Payment overview · 2025
General Payments
$315.01
17 reported records · 11 companies
Healthcare provider profile · identity verified
Igor N Bedarev, MD
Allopathic & Osteopathic Physicians|Family Medicine · INMAN, SC · NPI 1497069918
Verified facts
What the public records show
CMS Open Payments records show Igor N Bedarev, MD received $315.01 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.39 | 16.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.29 | 14.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.97 | 14.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.26 | 14.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.33 | 7.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.23 | 6.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.23 | 6.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.00 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.59 | 5.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.99 | 4.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.73 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $315.01 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.26 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.26 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.87 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 814 | 274 |
| Amlodipine Besylate | Amlodipine Besylate | 687 | 226 |
| Lisinopril | Lisinopril | 512 | 164 |
| Losartan Potassium | Losartan Potassium | 400 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 378 | 107 |
| Omeprazole | Omeprazole | 300 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 238 | 95 |
| Metformin Hcl | Metformin Hcl | 225 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 85 |
| Gabapentin | Gabapentin | 199 | 72 |
| Lorazepam | Lorazepam | 195 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 54 |
| Sertraline Hcl | Sertraline Hcl | 148 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 42 |
| Potassium Chloride | Potassium Chloride | 143 | 47 |
| Spironolactone | Spironolactone | 136 | 45 |
| Furosemide | Furosemide | 134 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 45 |
| Carvedilol | Carvedilol | 118 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 39 |
| Allopurinol | Allopurinol | 109 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 39 |
| Chlorthalidone | Chlorthalidone | 98 | 39 |
| Montelukast Sodium | Montelukast Sodium | 92 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 25 |
| Trazodone Hcl | Trazodone Hcl | 90 | 31 |
| Simvastatin | Simvastatin | 89 | 35 |
| Glipizide Er | Glipizide | 85 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 23 |
| Alendronate Sodium | Alendronate Sodium | 83 | 19 |
| Meloxicam | Meloxicam | 83 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 22 |
| Clonazepam | Clonazepam | 74 | 14 |
| Glipizide | Glipizide | 70 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 66 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 17 |
| Alprazolam | Alprazolam | 59 | 11 |
| Eliquis | Apixaban | 58 | 20 |
| Atenolol | Atenolol | 54 | 16 |
| Ezetimibe | Ezetimibe | 54 | 22 |
| Buspirone Hcl | Buspirone Hcl | 51 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Estradiol | Estradiol | 50 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 20 |
| Famotidine | Famotidine | 48 | 21 |
| Tramadol Hcl | Tramadol Hcl | 48 | 20 |
| Pregabalin | Pregabalin | 46 | 12 |
| Meclizine Hcl | Meclizine Hcl | 45 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Prednisone | Prednisone | 34 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | 14 |
| Ozempic | Semaglutide | 32 | 12 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Clotrimazole | Clotrimazole | 28 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Ondansetron Odt | Ondansetron | 27 | 19 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $315.01 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, ENTRESTO, FARXIGA, GEMTESA, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, Veozah | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error